{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:47:37Z","timestamp":1772916457134,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jacig.2025.100498","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T12:25:35Z","timestamp":1747830335000},"page":"100498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-9406","authenticated-orcid":false,"given":"Hirsh D.","family":"Komarow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Eisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica H.","family":"Brittain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2025.100498_bib1","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization","first-page":"62","article-title":"Mastocytosis","author":"Horny","year":"2008"},{"key":"10.1016\/j.jacig.2025.100498_bib2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jacig.2025.100498_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/CS20110340","article-title":"IL-6\/IL-6 receptor system and its role in physiological and pathological conditions","volume":"122","author":"Mihara","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jacig.2025.100498_bib4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clim.2005.01.011","article-title":"IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis","volume":"115","author":"Brockow","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jacig.2025.100498_bib5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1346-8138.2004.tb00664.x","article-title":"Up-regulation of IL-6 mRNA in peripheral blood mononuclear cells of patients with acute urticaria","volume":"31","author":"Fujii","year":"2004","journal-title":"J Dermatol"},{"key":"10.1016\/j.jacig.2025.100498_bib6","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1365-2222.2011.03789.x","article-title":"Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients","volume":"41","author":"Kasperska-Zajac","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jacig.2025.100498_bib7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/leu.2015.176","article-title":"Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression","volume":"30","author":"Mayado","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jacig.2025.100498_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/thx.2010.136523","article-title":"Sputum IL-6 concentrations in severe asthma and its relationship with FEV1","volume":"66","author":"Morjaria","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.jacig.2025.100498_bib9","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.jaci.2015.09.059","article-title":"IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3","volume":"137","author":"Desai","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2025.100498_bib10","article-title":"Regulation of reactive oxygen species and the antioxidant protein DJ-1 in mastocytosis","volume":"11","author":"Kim","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jacig.2025.100498_bib11","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/rheumatology\/kes131","article-title":"Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study","volume":"51","author":"Strand","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.jacig.2025.100498_bib13","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/14712598.2016.1217988","article-title":"Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis","volume":"16","author":"June","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jacig.2025.100498_bib14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: results of a phase II, randomised, double-blind, placebo-controlled study (ALIGN)","volume":"74","author":"Sieper","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacig.2025.100498_bib15","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2147\/OPTH.S68595","article-title":"Targeting interleukin-6 for noninfectious uveitis","volume":"9","author":"Lin","year":"2015","journal-title":"Clin Ophthal"},{"key":"10.1016\/j.jacig.2025.100498_bib16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/all.12842","article-title":"Development and validation of the mastocytosis quality of life questionnaire: MC-QoL","volume":"71","author":"Siebenhaar","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2025.100498_bib17","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/0959-8049(94)90182-1","article-title":"The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress","volume":"30A","author":"Portenoy","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jacig.2025.100498_bib18","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/all.12920","article-title":"Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis","volume":"71","author":"van Anrooij","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2025.100498_bib19","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.iac.2023.04.011","article-title":"World Health Organization classification and diagnosis of mastocytosis: update 2023 and future perspectives","volume":"43","author":"Valent","year":"2023","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jacig.2025.100498_bib20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s13063-021-05454-8","article-title":"Placebo response and effect in randomized clinical trials: meta-research with focus on contextual effects","volume":"22","author":"Hafliethadottir","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.jacig.2025.100498_bib21","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus placebo in indolent systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evid"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829325000992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829325000992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:22:37Z","timestamp":1762647757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829325000992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2772829325000992"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2025.100498","relation":{},"ISSN":["2772-8293"],"issn-type":[{"value":"2772-8293","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2025.100498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100498"}}